Is Regeneron Pharmaceuticals (REGN) One of the Best Gene-Editing Stocks to Buy According to Hedge Funds?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Canaccord Genuity analyst John Newman reaffirmed a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), setting a price target of $850.

Earlier on November 8, Regeneron Pharmaceuticals, Inc. reported positive results from Phase 2 clinical trials for its two investigational factor XI monoclonal antibodies, REGN7508 and REGN9933. The treatments target thrombosis, and the trials enrolled patients undergoing total knee replacement.

The company stated that both antibodies “demonstrated robust anti-clotting (antithrombotic) effects.” In particular, REGN7508 reduced the risk of postoperative venous thromboembolism (VTE) to 7.1%, outperforming apixaban (Eliquis), which has a rate of 12.4%. For REGN9933, the rate was 17.2%, numerically superior to enoxaparin’s 20.6%. Investigators highlighted that these results “confirm the role of factor XI in postoperative venous thromboembolism and suggest that these two distinct antibodies may enable flexibility for physicians to tailor anticoagulant therapy for patients with different risk profiles”.​ Regeneron said it plans to initiate broad Phase 3 trials for both factor XI antibodies before the end of this year.

Just a day earlier (November 7), the company had reported that its biologic drug Dupixent (dupilumab) – co-developed with Sanofi – achieved all primary and secondary endpoints in a Phase 3 trial for allergic fungal rhinosinusitis (AFRS), a rare sinus disease. The study assessed Dupixent in patients aged 6 years and older with AFRS. In the primary endpoint, sinus opacification scores (a radiological measure of nasal congestion) improved by 50.0% for patients administered Dupixent, compared to 9.8% for those who didn’t receive the treatment. In the secondary endpoint, the conditions of patients who received the therapy improved by 66.7% at 24 weeks and 80.6% at 52 weeks. The trial results will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 annual meeting.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company. It discovers, develops, and commercializes medicines for serious diseases, with a portfolio spanning ophthalmology, immunology, oncology, and rare conditions. Regeneron Pharmaceuticals is advancing genetic medicine through its Regeneron Genetics Center and proprietary platforms, focusing on in vivo CRISPR‑based gene editing in collaboration with Mammoth Biosciences.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best European Bank Stocks to Buy Now and 11 Best Solar Energy Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.